Condition: Non-Small Cell Carcinoma of Lung, TNM Stage 4 · Non-Small Cell Lung Cancer · EGFR Gene Mutation · Sponsor: University of Colorado, Denver
A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of therapeutic agents to improve outcomes.
This description comes directly from the study's public registry record.
Brandi Kubala · 303-724-1657 · brandi.kubala@cuanschutz.edu
Always discuss trial participation with your own doctor first.
| University of Colorado, Cancer Center | Aurora, Colorado, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03042221